

RESEARCH ARTICLE

FORMULATION AND EVALUATION OF BILAYER TABLET OF CANDESARTAN AND HYDROCHLOROTHIAZIDE FOR THE TREATMENT OF HYPERTENSION

*Ankit Pateriya, Mithun Bhowmick, Girijesh Kumar Pandey, Amit Joshi, Balkrishna Dubey

TIT College of Pharmacy, Bhopal, India

*Corresponding Author's E-mail: ankit_pateriya@yahoo.com , Contact No.:- +91-9685523140

ABSTRACT

The main purpose of this study was to design bilayered sustained release tablet of Candesartan and Hydrochlorothiazide to provide renoprotection in hypertension. The bilayered tablet was prepared by using super disintegrant Cross Carmellose, starch sodium glycolate, croscopolidone for Hydrochlorothiazide to provide its immediate release and Candesartan was made sustained released by using HPMC K4, K15 polymer. Lactose is used as diluents. The prepared different layer were characterized by different parameters like angle of repose, bulk density, tapped density, compressibility index, moisture content. The prepared bilayered tablet was characterized by physical and chemical parameters such as tablet thickness, hardness, diameter, weight variation, drug content, friability and in vitro drug release. The present studies concluded that bilayered tablet of Candesartan and Hydrochlorothiazide is novel approach to prevent hypertension.


Key words: Bilayered sustained release Tablet, Candesartan, Hydrochlorothiazide, Immediate release

INTRODUCTION

Some 600 million people worldwide have high blood pressure and nearly 3 million die every year as a direct result. Yet seven out of every 10 people with hypertension are not being treated adequately, according to WHO and the International Society of Hypertension (ISH). Combination drug therapy is recommended for patients whose blood pressure does not fall to optimal levels with single-drug treatment.

Bilayer tablet is new era for successful development of controlled release formulation along with various features to provide successful drug delivery system. Bilayer tablet is suitable for sequential release of two drugs in combination, separate two incompatible substances and also for sustained release tablet in which one layer is immediate release as loading dose and second layer is maintenance dose. The immediate release layer of bilayer tablet has worked as the loading dose and the sustained release layer has maintained therapeutic plasma drug concentration for prolonged time.

It is envisaged that the proposed work is designed as the Bilayer tablet of hydrochlorothiazide and candesartan. One layer of the bilayer tablet contains the hydrochlorothiazide as instant release, and the remaining second layer contains the candesartan as control Layer. Hydrochlorothiazide is a thiazide diuretic that helps prevent your body from absorbing too much salt, which can cause fluid retention. Candesartan is an angiotensin II receptor antagonists. Candesartan keeps blood vessels from narrowing, which lowers blood pressure and improves blood flow. The combination of Hydrochlorothiazide and Candesartan is used to treat high blood pressure (hypertension).



MATERIAL AND METHODS

Materials

Candesartan and Hydrochlorothiazide (Micro Lab. Hosur); HPMC K4 and K15 (Lobachem Pvt. Ltd., Mumbai); Sodium starch glycolate (Bioplus Life Science Bangalore); Cross carmellose sodium, Microcrystalline cellulose and Lactose anhydrous (Merck Pvt. Ltd., Mumbai); Magnesium stearate, PVP K30 and Talc (S.D. Fine Chemical Ltd, Mumbai)

Methods

Preformulation

Physicochemical Properties of candesartan and hydrochlorothiazide

A) Organoleptic evaluation

It refers to the evaluation by sensory characters-taste, appearance, odor, feel of the drug, etc.

B) Solubility (at room temp:)

We will check the solubility of both of drugs in water, hot water, 0.1N HCL, 0.1 NaOH, acetone, ethanol, chloroform, methanol at room temperature.

C) Identification Test

FTIR Spectroscopy

Infra-red spectrum is an important record which gives sufficient information about the structure of a compound. This technique provides a spectrum containing a large number of absorption band from which a wealth of information can be derived about the structure of an organic compound.

D) Loss on drying: Loss on drying directly measuring by IR moisture balance. Firstly calibrate the instrument by knob then take 5.000 gm sample (powder) and set the temp at 100°C to 105°C for 5 minutes and constant reading set the knob and check % moisture.

E) Determination of pH (1 w/v solution in water):

1gm of the Powder was taken and dissolved in 100ml of distilled water with sonication and filtered, pH of the filtrate was checked with standard glass electrode.

F) Melting point:

It is one of the parameters to judge the purity of drugs. In case of pure chemicals, melting points are very sharp and constant. Since the drugs contain the mixed chemicals, they are described with certain range of melting point. A small quantity of powder was placed into a fusion tube. That tube is placed in the melting point determining apparatus containing castor oil. The temperature of the castor oil was gradual increased automatically and read the temperature at which powder started to melt and the temperature when all the powder gets melted.

G) Bulk properties

A known quantity of powder was poured into the measuring cylinder carefully level the powder without compacting, if necessary and read the unsettled apparent volume, V_o , to the nearest graduated unit. Calculate the bulk density, in gm per ml gm/cc, by the formula

$$\text{Bulk density} = \text{Bulk Mass} / \text{Bulk Volume}$$

H) Compressibility index (Carr's index):

Compressibility index (C.I.) is an important measure that can be obtained from the bulk and tapped densities. Carr's index a material having values of less than 20% to 30% is defined as the free flowing material. Shown in Table 1.

It can be calculated as per given formula:

$$C.I. = \frac{\text{Tapped density} - \text{Bulk density}}{\text{Tapped density}} * 100$$

Table 1: Carr's index range

S. no.	% Comp. Index	Properties
1	5-12	Excellent
2	12-16	Good
3	18-21	Fair – passable
4	23-25	Poor
5	33-38	Very Poor
6	>40	Extremely poor

I) Hausner ratio:

It indicates the flow properties of the powder and is measured by the ratio of tapped density to bulk density. Shown in Table 2.

$$\text{Hausner ratio} = \text{Tapped density} / \text{Bulk Density}$$

Table 2: Hausner ratio and flow property characteristics

S. no.	Hausner ratio	Property
1.	0.0 - 1.2	Free flowing
2.	1.2 - 1.6	Cohesive powder

Standard value of Hausner ratio is 1.25.

J) Angle of repose:

The angle of repose is a relatively simple technique for estimating the flowability of a powder through a funnel and fall freely onto a surface. The height and diameter of the resulting cone is measured and using the following equation, the angle of repose can be calculated.

$$\tan \theta = h/r$$

Where h , r is the relatively height and radius of the powder cone.

For most pharmaceutical powders, the angle of repose values range from 25 to 45, with lower values indicating better flow characteristics. Values of angle of repose ≤ 30 usually indicate a free flowing material and angle ≥ 40 suggest a poorly flowing material.

k) MOISTURE CONTENT DETERMINATION

Principle: The titrimetric determination of water is based upon the quantitative reaction of water with an anhydrous solution of sulphur dioxide and iodine in the presence of a buffer that reacts with hydrogen ions. In the original titrimetric solution, known as Karl Fisher Reagents, the sulfur dioxide and iodine was dissolved in pyridine and methanol. The test specimen may be titrated with the reagent directly, or the analysis may be carried out by a residual titration procedure. The stoichiometry of the reaction is not exact, and the reproducibility of a determination depends upon such factors as the relative concentration of the reagent ingredients, the nature of the inert solvent used to dissolve the test specimen, and the technique used in the particular determination. Therefore, an empirically standardized technique is used in order to achieve the desired accuracy. Precision in the method is governed largely by the extent to which atmospheric moisture is excluded from the system. The titration of water is usually carried out with the use of anhydrous methanol as the solvent for the test specimen; however other suitable solvents may be used for special or unusual test specimens. (Note: Now-a-days pyridine free KF reagents are coming in which pyridine is replaced by the imidazole, because pyridine has carcinogenic effects).

L) DETERMINATION OF λ_{max} OF CANDESARTAN

Accurately weighed 10 mg of drug was dissolved in 10 ml of 6.8 PH buffer solution in 10 ml of volumetric flask. the resulted solution 1000 μ g/ml and from this solution 1 ml pipette out and transfer into 10 ml volumetric flask and volume make up with 6.8 PH buffer solution prepare suitable dilution to make it to a concentration range of 5-25 μ g/ml. The spectrum of this solution was run in 200-400 nm range in U.V spectrophotometer (Labindia-3000+). The Candesartan shows the absorbance maxima at 257 nm in 6.8 PH buffer solution.

M) DETERMINATION OF λ_{max} OF HYDROCHLOROTHIAZIDE

Accurately weighed 10 mg of drug was dissolved in 10 ml of 6.8 PH buffer solution (methanol used as cosolvent) in 10 ml of volumetric flask. The resulted solution 1000 μ g/ml and from this solution 1 ml pipette out and transfer into 10 ml volumetric flask and volume make up with 6.8 PH buffer solution prepare suitable dilution to make it to a concentration range of 5-25 μ g/ml. The spectrum of this solution was run in 200-400 nm range in U.V spectrophotometer (Labindia-3000+). The

Hydrochlorothiazide shows the absorbance maxima at 272 nm in 6.8 PH buffer solutions.

PHASE-I PREPARATION OF INSTANT LAYER OF HYDROCHLOROTHIAZIDE

Fast dissolving tablets of Hydrochlorothiazide were prepared by direct compression method after incorporating different superdisintegrants such as, croscarmellose sodium (Ac-Di-Sol), crospovidone and sodium starch glycolate in different concentrations. The above ingredients was weighed and mixed in geometric progression in a dry and clean mortar. Then the ingredients were passed through mesh #60.

Magnesium stearate as lubricant and talc as glidant were added in a final step and mixed, this blend was subjected to analysis of pre-compression parameters which included Angle of repose, Bulk density, Tap density, Carr's index and Hausner's ratio.

The Blend was compressed on 8 mm (diameter) fat punches on a 'Rimek mini press 16 station rotary compression machine. Eight formulations of Hydrochlorothiazide granules were prepared and each formulation contained one of the three disintegrant in different concentration. Each tablets weighing 100 mg, were obtained. Composition of tablets is mentioned in Table 3.

Table 3: Composition of Hydrochlorothiazide Fast Dissolving Tablets

Ingredients(mg)	Formulation code								
	TM1	TM2	TM3	TM4	TM5	TM6	TM7	TM8	TM9
Hydrochlorothiazide	25	25	25	25	25	25	25	25	25
Sodium Starch glycolate	4	6	8	—	—	—	—	—	—
Croscarmellose odium	—	—	—	4	6	8	—	—	—
Crospovidone	—	—	—	—	—	—	4	6	8
Microcrystalline cellulose	65	65	65	65	65	65	65	65	65
Magnesium stearate	06	04	02	06	04	02	06	04	02
Total weight	100	100	100	100	100	100	100	100	100

EVALUATION OF POSTCOMPRESSION PARAMETER

1. Shape and colour of tablets:

Uncoated tablets were examined under a lens for the shape of the tablet and colour was observed by keeping the tablets in light.

• Thickness test

Three tablets were picked from each formulation randomly and thickness was measured individually. It is expressed in mm and standard deviation was also calculated. The tablet

thickness was measured using dial-caliper (Mitutoyo, Japan).

• Weight variation test

Twenty tablets were selected randomly from each formulation and average weight was determined. The tablets were weighed individually and compared with average weight. The U.S Pharmacopoeia allows a little variation in the weight of a tablet. The following percentage deviation in weight variation is allowed (Table No.6.7).

Table 4: Percentage deviation in weight variation

S. NO.	Average Weight of A Tablet	Percentage Deviation
1.	130 mg or less	10
2.	More than 130 mg and less than 324 mg	7.5
3.	324 mg or more	5

In all the formulations the tablets weight is more than 130 mg and less than 324 mg, hence 7.5% maximum difference allowed.

• Hardness test

The hardness of tablet was measured by Pfizer hardness tester and results were expressed in Kg/cm².

• Friability test

For this, 20 tablets were taken from each formulation and the friability was determined using Roche friabilator. The equipment was run for 4min at 25 revolutions per minute. The tablets were taken out, dedusted and reweighed and

% friability was calculated. The friability was determined as the mass loss in percent according to Equation:-

$$\% \text{Friability} = (\text{Loss in weight} / \text{Initial weight}) \times 100$$

The test complies if tablets not lose more than 1% of their weight

• Uniformity of drug content:

The test is mandatory for tablets with 10 mg or less weight of active ingredient. Ten randomly selected tablets from each formulation (F1 to F9) were finely powdered and Drug equivalent to 10 mg of drug dissolved in 10 ml 0.1 N HCl (simulated gastric fluid of pH 1.2 without

enzymes) sonicate it for 20 minutes, till the entire drug leached out from complex, then the solution was filtered through whatman filter paper No. 41. From this Solution take 1ml and Diluted up to 100 ml with 0.1 N HCl and the drug content was determined spectrophotometrically at 272.0 nm.

PREPARATION OF CANDESARTAN MATRIX TABLET

Direct compression was followed to manufacture the gas generating floating tablets of simvastatin. All the polymers selected, drug and excipients were passed through sieve no. 40 before using into formulation. Polymers selected for

tablets are HPMC K15, HPMC K4, PVP-K30. Excipients like Lactose anhydrous, Talc, Magnesium Stearate were selected for the study.

Steps involved in the manufacture of tablets

- First the drug, polymer and other excipients selected were passed through 40- mesh sieve. Required quantity of drug, polymer and excipients were weighed properly and transferred into polyethylene bag and the blend was mixed for at least 15 min.

The blend obtained was then lubricated by adding 1% magnesium stearate and again mixed for another 5min.

Table 5: Various formulation of Candesartan Matrix tablet

Excipients	F1	F2	F3	F4	F5	F6	F7	F8	F9
Candesartan	32	32	32	32	32	32	32	32	32
HPMC K 4	130	120	110	-	-	-	65	60	55
HPMC K 15	-	-	-	130	120	110	65	60	55
Lactose anhydrous	18	28	38	18	28	38	18	28	38
PVP-k30	16	16	16	16	16	16	16	16	16
Talc	2	2	2	2	2	2	2	2	2
Magnesium stearate	2	2	2	2	2	2	2	2	2
Total	200	200	200	200	200	200	200	200	200

EVALUATION OF MATRIX TABLET

All the tablets were evaluated for following different parameters which includes;

1. General Appearance

Five tablets from different batches were randomly selected and organoleptic properties such as color, odor, taste, shape, were evaluated. Appearance was judged visually.

Very good (+++), good (++), fair (+) poor (-), very poor (-).

2. Thickness and diameter

Thickness and diameter of tablets were determined using Vernier caliper. Five tablets from each batch were used, and an average value was calculated.

3. Hardness

For each formulation, the hardness of five tablets was determined using the Monsanto hardness tester (Cadmach).

4. Friability

The friability of a sample of 10 tablets was measured using a Friability tester (Electro Lab). Ten tablets were weighed, rotated at 25 rpm for 4 minutes. Tablets were reweighed after removal of fines (dedusted) and the percentage of weight loss was calculated.

5. Uniformity of weight

Twenty tablets were randomly selected from each batch individually weighed, the average weight and standard deviation of 20 tablets was calculated.

6. Drug content

Twenty tablets were taken and amount of drug present in each tablet was determined. The tablets were crushed in a mortar and the powder equivalent to 100 mg of drug was

transferred to 100ml standard flask. The powder was dissolved in 50 ml of pH 6.8 Phosphate Buffer and made up to volume with buffer. The sample was mixed thoroughly and filtered through a 0.45 μ membrane filter. The filtered solution was diluted suitably and analyzed for drug content by UV spectrophotometer at a λ_{max} of 257.0 nm using of pH 6.8 Phosphate Buffer as blank.

• Dissolution rate studies

In vitro drug release of the sample was carried out using USP- type II dissolution apparatus (Paddle type). The dissolution medium, 900 ml pH 6.8 Phosphate Buffer (Tween 20, 0.1%) was placed into the dissolution flask maintaining the temperature of 37 \pm 0.50c and rpm of 50. One Candesartan Control layer tablet was placed in each basket of dissolution apparatus. The apparatus was allowed to run for 12 hours. Sample measuring 4 ml were withdrawn after 30 min., 1.0 hr, 1.30 hr, 2.0 hr, 3hr., 4.0 hr, 6.0 hr, 8.0hr 10.0 hr, 12 hour using 4 ml pipette. The fresh dissolution medium was replaced every time with the same quantity of the sample.

FORMULATION OF BILAYER TABLETS

Optimized batch of Instant Layer (TM4) and Optimized batch of Sustain layer(F7) used to formulate Bilayer tablet of Hydrochlorothiazide and Candesartan. Procedure of formulation same as method as previous.

All the tablets were evaluated for following different parameters which includes;

1. General Appearance

Five tablets from different batches were randomly selected and organoleptic properties such as color, odor, taste, shape, were evaluated. Appearance was judged visually.

Very good (+++), good (++), fair (+) poor (-), very poor (-).

2. Thickness and diameter

Thickness and diameter of tablets were determined using Vernier caliper. Five tablets from each batch were used, and an average value was calculated.

3. Hardness

For each formulation, the hardness of five tablets was determined using the Monsanto hardness tester (Cadmach).

4. Friability

The friability of a sample of 10 tablets was measured using a Friability tester (Electro Lab). Ten tablets were weighed, rotated at 25 rpm for 4 minutes. Tablets were reweighed after removal of fines (dedusted) and the percentage of weight loss was calculated.

5. Uniformity of weight

Twenty tablets were randomly selected from each batch individually weighed, the average weight and standard deviation of 20 tablets was calculated.

6. Drug content

Twenty tablets were taken and amount of drug present in each tablet was determined. The tablets were crushed in a mortar and the powder equivalent to 32 mg of Candesartan was transferred to 100ml standard flask. The powder was dissolved in 50 ml of methanol and made up to volume with methanol. The sample was mixed thoroughly and filtered through a 0.45 μ membrane filter. The filtered solution was further diluted 1 ml to 10ml suitably (32 ppm of candesartan and 25 ppm of Hydrochlorothiazide) and Determine the Conc. of both drugs using Simultaneous estimation method

7. Dissolution rate studies

In vitro drug release was performed according to the USP dissolution apparatus II at 50 rpm and 37 \pm 0.5°C temperature over a 12 hrs period for Candesartan SR and 2 hr for Hydrochlorothiazide IR, using an automated paddle

dissolution system (Labindia). A minimum of 6 tablets per batch were tested.

The media used was 0.1N HCl at a pH 1.2 and a volume of 900 ml for the first 2 hours after and then pH of 6.8 and maintained at 37 \pm 0.5°C upto 12 Hours. Test sample (4ml) was withdrawn at particular time interval and replaced with fresh dissolution media maintained at the same temperature and the concentration of dissolved drug was determined using U.V. (Ultraviolet Labindia 3000+) spectrophotometer at λ_{max} 257 nm for Candesartan and 272.0 nm for Hydrochlorothiazide.

RESULTS AND OBSERVATION

PREFORMULATION

PHYSICO-CHEMICAL PROPERTIES OF CANDESARTAN AND HYDRO

-CHLOROTHIAZIDE

A). Organoleptic evaluation:

Table 6: Organoleptic property of Candesartan

Color	white
Odor	characteristic

Table 7: Organoleptic property of Hydrochlorothiazide

Color	White
Odor	Characteristic

B) Solubility:

Solubility study of Candesartan and hydrochlorothiazide has been done in various solvent such as water, Phosphate buffer pH 6.8, Phosphate buffer pH 7.4 and 0.1 N HCl solution. We were found that a solubility of candesartan and hydrochlorothiazide were slightly soluble in a 0.1 N HCl solution.

Table 8: Solubility in various solvent

S. No.	Solvent	Candesartan	Hydrochlorothiazide
1	Water	In soluble	In soluble
2	Ethanol	Freely soluble	Soluble
3	Methanol	Freely soluble	Soluble
4	Acetone	Freely soluble	Soluble
5	0.1N HCl	Slightly soluble	Slightly soluble
6	6.8 pH buffer	Soluble	Soluble
7	7.4 pH buffer	Soluble	Soluble


C) Identification test by FTIR:

Identification of Candesartan and Hydrochlorothiazide by FTIR Spectroscopy with respect to marker compound

Candesartan and Hydrochlorothiazide was obtained as White or almost white crystalline powder. It was identified from the result of IR spectrum as per specification.

Sample of pure Candesartan and Hydrochlorothiazide

The IR spectrum of sample drug shows the peak values which are characteristics of the drug and the graph was shown in figure no. 7.1 and 7.2.



E) Loss on Drying (LOD):

Procedure: Loss on drying directly measuring by IR moisture balance. Firstly calibrate the instrument by knob then take 1.000 gm sample (powder) and set the temp at 100°C to 105°C for 5 minutes and constant reading set the knob and check % moisture.

Result: The percentage of loss on drying of Candesartan and hydrochlorothiazide **0.020 %w/w** and **0.0255 %w/w**.

F) Determination of pH (1 w/v solution in water):

The pH determination of Candesartan and Hydrochlorothiazide was done by Digital pH meter and found to be 6.4 and 4.43.

G) Melting Point:

Procedure: A small quantity of powder was placed into a fusion tube. That tube is placed in the melting point determining apparatus containing castor oil. The

temperature of the castor oil was gradually increased automatically and read the temperature at which powder started to melt and the temperature noted when all the powder gets melted.

Result: Melting point of Candesartan and Hydrochlorothiazide determine by Melting point apparatus at **157-160°C** and **265-280°C**.

H) Flow Property of Candesartan and Hydrochlorothiazide Powder:

- Bulk density:**

A known quantity of powder was poured into the measuring cylinder carefully level the powder with out compacting, if necessary and read the unsettled apparent volume, V_o , to the nearest graduated unit. Calculate the bulk density, in gm/ml gm/cc, by the formula.

$$\text{Bulk density} = \text{Bulk Mass} / \text{Bulk Volume}$$

Table 9: Bulk Density of Candesartan and Hydrochlorothiazide

S. No.	Density	Candesartan	Hydrochlorothiazide
1	Untapped density	0.22 g/cc	0.4 g/cc
2	Tapped density(after 50 tapping)	0.40 g/cc	0.71 g/cc

- Compressibility Index (%)**

$$C.I = \frac{100 (V_o - V_t)}{V_o} \quad \text{OR} \quad C.I = \frac{\text{Tapped density} - \text{Bulk density}}{\text{Tapped density}} * 100$$

Result: The compressibility index of Candesartan and hydrochlorothiazide respectively is **45%** and **44.2%**.

- Hausner ration:**

$$\text{Hausner Ratio} = \text{Tapped density} / \text{Bulk Density}$$

Result: The Hausner ration of candisaratr and hydrochlorothiazide respectively is **1.818** and **1.77**.

- Angle of Repose**

Procedure: The angle of repose is a relatively simple technique for estimating the flowability of a powder through a funnel and fall freely onto a surface. The height and diameter of the resulting cone is measured and using the following equation, the angle of repose can be calculated. Weigh 10 gm of drug (Candesartan and Hydrochlorothiazide) powder accurately, and pass through the fennel height up to 2.5 cm from surface and measure the height and diameter by scale.

$$\tan \theta = h/r$$

Where h, r is the relatively height and radius of the powder cone.

Result: The Angle of repose of Candesartan and hydrochlorothiazide **38.0°** & **37.0°** degree respectively.

Result: Partical size pass through 40# is **100 (%w/w)**.

I) Moisture by Karl-Fischer Apparatus (KF)

Result: The Moisture content of Candesartan and hydrochlorothiazide is 0.1095 and 0.073% respectively.

7.1.2. DETERMINATION OF λ_{MAX} BY UV-VISIBLE SPECTROSCOPY

Standard solution (10g/ml) of pure Candesartan and Hydrochlorothiazide was prepared. The pure drug solutions were scanned on UV spectrophotometer, which showed maximum absorbance at 257.0nm and 272.0nm for Candesartan and hydrochlorothiazide respectively.

- Determination of λ_{max} of Candesartan**




Figure 5: Determination of λ_{max} of Candesartan at 257.0nm




Figure 6: 3D Spectrum of Determination of λ_{\max} of Candesartan at 257.0nm

- Determination of λ_{\max} of Hydrochlorothiazide**




Figure 7 Determination of λ_{\max} of Hydrochlorothiazide at 272.0nm




Figure 8: 3D Spectrum of Determination of λ_{\max} of Hydrochlorothiazide at 272.0nm

- Preparation of Calibration Curve of Candesartan and Hydrochlorothiazide**

Preparation of Calibration Curve of Candesartan

Accurately weighed 10 mg of pure Candesartan was dissolved in 2.0 ml of methanol and volume make upto 10 ml with 6.8 pH buffer solution in 10 ml of volumetric flask and prepare suitable dilution to make it to a concentration of 1000 μ g/ml make adequate of sample with concentration range of 5-25 μ g/ml with with 6.8 pH buffer solution. The spectrum of this solution was run in 200-400 nm range in U.V spectrophotometer.




Figure 9: Standard Calibration Curve of Candesartan

Regression Equation

$$Y = mx + c,$$

$$Y = \text{AUC}$$

$$m = \text{slope} = 0.014$$

$$X = \text{Conc. in g/ml}$$

$$c = \text{Intercept} = 0.005$$

$$r^2 = 0.999$$

- Preparation of Calibration Curve of Hydrochlorothiazide**

Accurately weighed 10 mg of pure Hydrochlorothiazide was dissolved in 2.0 ml of methanol and volume make upto 10 ml with 6.8 pH buffer solution in 10 ml of volumetric flask and prepare suitable dilution to make it to a concentration of 1000 μ g/ml make adequate of sample with concentration range of 5-25 μ g/ml with with 6.8 pH buffer solution. The spectrum of this solution was run in 200-400 nm range in U.V spectrophotometer.




Figure 10: Standard Calibration Curve of Hydrochlorothiazide

Regression Equation

$$Y = mx + c,$$

$$Y = \text{AUC}$$

$$m = \text{slope} = 0.032$$

$$X = \text{Conc. in g/ml}$$

$$c = \text{Intercept} = 0.027$$

$$r^2 = 0.995$$

• Optical parameters of Candesartan and Hydrochlorothiazide

Table 10: Result of Optical Parameter of Candesarta and Hydrochlorothiazide

S. No.	Parameters	Observation Candesartan	Observation Hydrochlorothiazide
1	λ_{\max}	257.0 nm	272.0
2	Beer's law limit ($\mu\text{g/mL}$)	5-25 $\mu\text{g/mL}$	5-25 $\mu\text{g/mL}$
3	Regression equation	$Y=0.014x-0.005$	$Y=0.035x+0.010$
4	Correlation Coefficient (r^2)	0.999	0.999

7.1.3. COMPATIBILITY STUDIES OF DRUG AND EXCIPIENTS

In the compatibility testing program, blends of drug and excipients are prepared by triturating the drug with Individual excipients.

Procedure: Take 50 mg accurately weigh of drug dry powder and 50 mg of excipients and mix the blend of drug and excipients and binary/tertiary blends of extract and excipients were prepared and transferred to inert glass vials. The mouths of the vials were covered with rubber closures followed by the aluminum seal caps. Binary/tertiary blends of extract and excipients, drug neat and excipients were stored at 4°C (refrigerator) as control; and at 40°C/75%RH for accelerated stability studies for 4 weeks. The visual observations (color, flow, & sticking) were recorded for initial and at the end of the first, second, third and fourth week.

7.2. PHASE I- PREPRATION OF INSTANT LAYER OF HYDROCHLOROTHIAZIDE

7.2.1. Evaluation of Pre-compression Parameters:

Blend ready for compression containing drug and various excipients was subjected for pre-compression parameters

to study the flow properties of granules, to achieve uniformity of tablet weight.

A) Angle of repose (θ):

The data obtained for angle of repose for all the formulations were tabulated in Table No.7.8. The values were found to be in the range of 34° to 41°. All the formulations prepared showed the angle of repose less than 41°, which reveals passable flow property.

B) Loose Bulk Density and Tapped Bulk Density:

Loose bulk density (LBD) and tapped bulk density (TBD) for the blend is shown in Table No.7.8 The loose bulk density and tapped bulk density for all the formulation blend varied from 0.33 gm/cm³ to 0.34 gm/cm³ and 0.50 gm/cm³ to 0.53 gm/cm³ respectively.

C) Carr's compressibility index and Hausner's ratio:

The results of Carr's consolidation index or compressibility index (%) for the entire formulation blend ranged from 28.30 to 40.38. The directly compressible granulations had shown excellent compressibility index values which results in Poor flow properties.

The results of Hausner's ratio for all the formulation blend is less than 0.570, which shows good flow property.

Table 11: Pre-Compression Parameters of Hydrochlorothiazide

Formulation code	Parameters				
	Loose Bulk density(gm/ml)	Tapped bulk density(gm/ml)	Carr's Index (%)	Hausner's Ratio	Angle of Repose
TM1	0.33	0.50	34.00	1.515	37°
TM2	0.32	0.51	37.25	1.594	38°
TM3	0.31	0.52	40.38	1.677	34°
TM4	0.33	0.53	37.74	1.606	40°
TM5	0.30	0.50	40.00	1.667	38°
TM6	0.34	0.51	33.33	1.500	41°
TM7	0.32	0.52	38.46	1.625	39°
TM8	0.38	0.53	28.30	1.395	37°
TM9	0.35	0.50	30.00	1.429	37°

7.2.2. Evaluation of Post-compression parameters

A) Shape and colour of tablets:

Formulations prepared were randomly picked from each batch examined under lens for shape and in presence of light for colour. Tablets showed flat, circular shape in pinkish colour due to add of Colouring agent.

B) Thickness test

Thickness of the tablets was measured by dial caliper by picking randomly from all the batches. The results of

thickness for tablets were shown in Table No. The mean thickness was (n=3) almost uniform in all the formulations and values ranged from 1.40 ± 0.10 mm. The standard deviation values indicated that all the formulations were within the range.

C) Weight variation test

The weight variation test is done to ensure the tablet contains the proper amount of drug. All the tablets passed weight variation test as the average percentage weight

variation was within the pharmacopoeial limits of $\pm 10\%$ (Table 7.9).

D) Hardness test

The hardness of all the tablets prepared was maintained within the 2.00 kg/cm^2 to 4.00 kg/cm^2 . All the tablets maintained hardness in the range $2.51 \pm 0.71 \text{ kg/cm}^2$ to $3.59 \pm 0.51 \text{ kg/cm}^2$ for formulations were almost uniform.

E) Friability test

The study results tabulated in Table no.7.9 was found to be well within the approved range ($<1\%$) in all designed formulations. The formulations TM-1 and TM-8 showed slightly higher than the other. This might be due to excess fines or due to improper granulation, but the values were found to be within the limit. Thus tablets possess good mechanical strength.

F) Uniformity of drug content:

The content uniformity was performed for all the nine formulations and results are tabulated in Table No.7.9. Three trials from each batch were analyzed

spectrophotometrically. The average value and standard deviations of all the formulations were calculated. The drug content in different formulation was highly uniform and in the range of 98.51 ± 0.75 – $99.53 \pm 0.42 \%$. The results were within the acceptable range and that indicated uniformity of mixing. The cumulative percentage drug released by each tablet in the in vitro release studies was based on the average drug content present in the tablet.

G) In-vitro disintegration time:

It was observed that the disintegration time of tablets decreased with increase in the concentration of the superdisintegrants. Based on the disintegration results (Table 7.10), the formulation containing croscopolidone (7.5%) showed the fastest disintegration.

Among the different formulations, TM4 was chosen as optimized batch containing croscarmillose sodium (5%) as superdisintegrant, as it has produced the ODT having least disintegration time of $12.0 \pm 0.21 \text{ sec}$.

Table 12: Post-Compressional Parameters of All Formulations-I

Formulation code	Hardness test (kg/cm^2) $\pm \text{SD}$, n=3	Friability (%) $\pm \text{SD}$, n=10	Weight variation (%) n=10	Thickness (mm) $\pm \text{SD}$, n=5	Drug Content (%) $\pm \text{SD}$, n=3
TM1	3.13 ± 0.21	0.8217 ± 0.01	Passes	1.42 ± 0.03	99.41 ± 0.42
TM2	3.70 ± 0.30	0.7262 ± 0.05	Passes	1.45 ± 0.05	99.77 ± 0.51
TM3	3.51 ± 0.50	0.5314 ± 0.03	Passes	1.41 ± 0.03	98.53 ± 0.71
TM4	3.73 ± 0.29	0.6425 ± 0.11	Passes	1.40 ± 0.06	99.41 ± 0.49
TM5	3.81 ± 0.51	0.6346 ± 0.05	Passes	1.44 ± 0.03	99.33 ± 0.66
TM6	3.50 ± 0.40	0.7114 ± 0.16	Passes	1.46 ± 0.05	98.51 ± 0.75
TM7	3.66 ± 0.29	0.5612 ± 0.07	Passes	1.40 ± 0.04	99.57 ± 0.42
TM8	2.77 ± 0.71	0.8554 ± 0.11	Passes	1.43 ± 0.05	98.33 ± 0.62
TM9	3.12 ± 0.42	0.7377 ± 0.15	Passes	1.42 ± 0.04	99.65 ± 0.48

Table 13: Post-compressional Parameters of All Formulations-II

Formulation code	In-vitro Disintegration Time(sec.) (n=3) Mean \pm SD
TM1	3.48 ± 0.56
TM2	6.40 ± 0.71
TM3	5.34 ± 0.41
TM4	12.00 ± 0.22
TM5	33.34 ± 1.23
TM6	1.50 ± 1.53
TM7	1.54 ± 0.96
TM8	1.03 ± 0.69
TM9	32.45 ± 1.15

7.3. PHASE II- PREPARATION OF CANDESARTAN MATRIX TABLET

Table 14: Result of Pre Compression Properties of Candesartan sustained layer

Material	Angle of repose(Degree)	Bulk density(gm/ml)	Tapped density(gm/ml)	Compressibility index	Hausner ratio
F1	36	0.38	0.52	26.92	1.37
F2	33	0.37	0.50	26.00	1.35
F3	37	0.35	0.51	31.37	1.46
F4	38	0.39	0.53	26.42	1.36
F5	35	0.38	0.52	26.92	1.37
F6	34	0.39	0.53	26.42	1.36
F7	34	0.40	0.52	23.08	1.30
F8	38	0.38	0.51	25.49	1.34
F9	33	0.36	0.51	29.41	1.42

Table 15: Results of Post Compression Properties of Candesartan sustained layer

Formulation code	Thickness (mm)	Hardness (kg/cm ²)	Weight variation	Friability (%)	Drug content (%)
F1	3.5	6.5	Passes	0.83	99.12
F2	3.7	6.4	Passes	0.67	99.25
F3	3.5	6.3	Passes	0.66	99.23
F4	3.6	6.4	Passes	0.78	99.21
F5	3.6	6.5	Passes	0.66	99.10
F6	3.4	6.2	Passes	0.89	99.56
F7	3.5	6.3	Passes	0.74	99.89
F8	3.4	6.5	Passes	0.99	99.54
F9	3.6	6.2	passes	0.89	99.26

RELEASE KINETICS OF CANDESARTAN MATRIX TABLET




Figure 11: Zero order release kinetics data Candesartan Matrix tablet with HPMC K-4 as Binder




Figure 12: Zero order release kinetics data Candesartan Matrix tablet with HPMC K-15 as Binder




Figure 13: Zero order release kinetics data Candesartan Matrix tablet with HPMC K-4+ HPMC K-15 as Binder




Figure 14: First order release kinetics data Candesartan Matrix tablet with HPMC K-4 as Binder




Figure no 15: First order release kinetics data Candesartan Matrix tablet with HPMC K-15 as Binder




Figure 16: First order release kinetics data Candesartan Matrix tablet with HPMC K-4 + HPMC K-15 as Binder




Figure 17: Higuchi release kinetics data Candesartan Matrix tablet with HPMC K-4 as Binder




Figure 18: Higuchi release kinetics data Candesartan Matrix tablet with HPMC K-15 as Binder




Figure 19: Higuchi release kinetics data Candesartan Matrix tablet with HPMC K4 + K-15 as Binder




Figure 20: Korsmayer Papas release kinetics data Candesartan Matrix tablet with HPMC K4 as Binder




Figure 21: Korsmayer Papas release kinetics data Candesartan Matrix tablet with HPMC K-15 as Binder




Figure 22: Korsmayer Papas release kinetics data Candesartan Matrix tablet with HPMC K4 + K-15 as Binder

Table 16: Kinetic data of Candesartan Matrix Tablet in comparison with All Formulation

FORMULATION	REGRATION COEFFICIENT	ZERO ORDER	FIRST ORDER	HIGUCHI	KORSMAYER PAPAS
F1	r ²	0.891	0.924	0.978	0.975
F2	r ²	0.881	0.920	0.981	0.983
F3	r ²	0.848	0.917	0.982	0.986
F4	r ²	0.910	0.965	0.986	0.999
F5	r ²	0.862	0.959	0.982	0.979
F6	r ²	0.871	0.980	0.993	0.983
F7	r ²	0.951	0.673	0.986	0.999
F8	r ²	0.920	0.974	0.982	0.992
F9	r ²	0.904	0.966	0.993	0.989

RESULTS OF POST COMPRESSION PROPERTIES OF BILAYER TABLETS

Table 17: Results of post compression property of bilayer tablets

Formulation code	Hardness (kg/cm ²) ±SD, n=3	Friability (%) ± SD, n=10	Weight variation (%) n=10	Thickness (mm) ±SD, n=5	Drug Content (%) ±SD, n=3
TM1	7.12 ± 0.21	0.8217± 0.01	Passes	6.00 ±0.03	99.53±0.42
TM2	7.70 ± 0.30	0.7262 ±0.05	Passes	6.01 ±0.05	99.41±0.51
TM3	7.51 ± 0.50	0.5314 ±0.03	Passes	6.01 ±0.03	98.77±0.71
TM4	7.73 ± 0.29	0.6425 ±0.11	Passes	6.00 ±0.06	99.12±0.49
TM5	7.81 ± 0.51	0.6346 ±0.05	Passes	6.01 ±0.03	99.33±0.66
TM6	7.50 ± 0.40	0.7114 ±0.16	Passes	6.01 ±0.05	98.51±0.75
TM7	7.66 ± 0.29	0.5612 ±0.07	Passes	6.01 ±0.04	99.65±0.42
TM8	7.77 ± 0.71	0.8554 ±0.11	Passes	4.54 ±0.05	98.80±0.62
TM9	7.12± 0.42	0.7377 ±0.15	Passes	4.56 ±0.04	99.27±0.48

In vitro drug release study of Bi-layered Tablet of Optimized Formulation




Figure 23: release of Hydrochlorothiazide

In vitro Drug release study of Optimized Formulation No. TM-4 of Instant layer and optimized formulation No. F-7 of Matrix layer.




Figure 24: release of Candesartan

In the present study seven formulations with variable concentration of polymers (HPMC K-4 and K-15) prepared by direct compression method and evaluated for physiochemical properties, buoyancy lag time and in vitro drug release. The results indicated that optimized the gastric fluid, formulation F7 of matrix tablet and TM4 formulation of instant release on immersion in 0.1N HCl solution for 2 hour and then at pH 6.8 phosphate buffer at $37 \pm 0.5^\circ\text{C}$ tablets immediately and remain buoyant upto 12hrs without disintegration.

These two factors are essential for the tablet to acquire bulk density < 1 , so that it remains buoyant on The In vitro drug release data of the optimized formulation was subjected to goodness of fit test by linear regression analysis according to zero order, first order kinetic equation, Higuchi's and Korsmeyer's models in order to determine the mechanism of drug release. When the regression coefficient values of were compared, it was observed that 'r' values of first order was maximum i.e 0.999 hence indicating drug release from formulations was found to follow Korsmeyer's models.

REFERENCES

1. Talukder R, Fassihi R. Gastroretentive Delivery Systems: A Mini Review. *Drug Dev Ind Pharm*. 2004; 30(10): 1019-28.
2. Garg R, Gupta GD. Progress in Controlled Gastroretentive Delivery Systems. *Trop J Pharm Res*. 2008, Sep; 7(3): 1055-66
3. Patil JM, Hirlekar RS, Gide PS, Kadam VJ. Trends in floating drug delivery systems. *J Sci Ind Res*. 2006 Jan; 65:11-21
4. Shaha SH, Patel JK, Pundarik akshudu K, Patel NV. An Overview of a gastro-retentive floating drug delivery system. *Asian Journal of Pharmaceutical Sciences*. 2009 Jan; 4(1): 65-80
5. <http://www.pharmainfo.net/pharma->
6. Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Floating Drug Delivery Systems: A Review. *AAPS Pharm Sci Tech*. 2005 Oct 19; 6(3): E372-E390
7. Raza JA, Babb JD, Movahed A. Optimal management of hyperlipidemia in primary prevention of cardiovascular disease. *International Journal of Cardiology*. 2004 Dec; 97(3): 355-66
8. Grundy SM. Atherogenic Dyslipidemia Associated with Metabolic Syndrome and Insulin Resistance. *Clinical Cornerstone*. 2006; 8(1): S21-S27
9. Jain NK. Progress in controlled and Novel Drug Delivery Systems. 1st ed Delhi: CBS Publishers and Distributors; 2004. P.76-95
10. Vyas SP, Khar RK. Controlled drug delivery concepts and advances. 1st ed. Delhi: M.K. Jain for Vallabh Prakashan; 2002. P.196-215
11. Metkar Vishal, Kumar Anuj, Pant Pankaj, Pal Deepti, Sahu Shraddha, Shurngarpure Mansee, Madhusudan Dutta, Formulation development and evaluation of Bilayer tablets of Lornoxicam 2012, 4 (2): 173-179
12. Hariprasanna R.C, Qamar Jamal Ahmad, Upendrakulkarni Design and Evaluation Twice Daily Lornoxicam Bi-Layer Matrix Tablets By Using Hydrophilic Polymer Sodium Alginate Issue 2 (Vol. 1) 2011
13. Prabhakar Shirse, Formulation and Evaluation of Bilayer Tablets of Diclofenac Sodium with Ranitidine HCL for Sustained and Immediate Release 02 (05); 2012: 136-141
14. Hosna Banu, Mostafa Reaj Sahariar, Muhammad Shahdaat Bin Sayeed, Irin Dewan and S.M. Ashraful Islam Formulation development of bi-layer acetaminophen tablets for extended drug release 2011, 3(6):348-360
15. Sachin Gowardipe, K. Jaganathan, R. Sambath Kumar, P. Peruma Formulation and In Vitro Evaluation of Lamivudine And zidovudine Controlled Release Bilayer Matrix Tablet vol 3 Issue 1 (Jan-Mar) - 2012s
16. Durga Prasad Pattanayak* and Subash C. Dinda Bilayer tablet formulation of metformin hydrochloride and glimepiride: A novel approach to improve therapeutic efficacy, 1(1): Jan-Mar: (2011), 1-4
17. Sharif et al, Design and Evaluation of Modified Release Bilayer Tablets of Flurbiprofen 2011, 20, 3, 343-349
18. Shirse P. Formulation and Evaluation of Bilayered Tablets of hydrochloride For Immediate And Sustained Release 2012 July; 3(3): (P) 148 – 160
19. Karwa P, Kasture PV, Formulation and in vitro evaluation of Bilayer Tablets of Zolpidem tartrate for Biphasic Drug Release Vol.3, No.4, pp 1919-1929, Oct-Dec 2011
20. Chinam Niranjana Patra, Arethi Bharani, Kumar hemant, Kumar Pandit, Satya Prakash Singh, Meduri Vimala Devi, Design And Evaluation of Sustained Release Bilayer Tablets of Propranolol Hydrochloride 57 (2007) 479-489
21. MANaem. A Mahmood, SA Khan and Z Shahiq Development and Evaluation of Controlled-Release Bilayer Tablets Containing Microencapsulated Tramadol and Acetaminophen 2010; 9 (4): 347-354
22. Muthukumarani M, Dhachinamoorthi D, Chandra Sekhar KB, Fabrication and evaluation of sustained release mucoadhesive bilayer tablets containing nifedipine 2012, 3 (3):367-376
23. Swamy PV. Kinagi MB, Biradar S. S., Gada S. N. and Shilpa H Formulation Design and Evaluation of Bilayer Buccal Tablets of Granisetron Hydrochloride 2011/ Vol 45/ Issue 3
24. Ali Sharif1, Mahboob E-Rabbani2, Muhammad Furqan Akhtar1, Bushra Akhtar2, Ammara Saleem2, Kalsoom Farzana2, Atif Usman2, Ghulam Murtaza3 Design and Evaluation of Modified Release Bilayer Tablets of Flurbiprofen 2011, 20, 3, 343-349

CONCLUSION

Bilayer tablet is improved beneficial technology to overcome the shortcoming of the single layered tablet. There is various application of the bi-layer tablet it consist of monolithic partially coated or multilayered matrices. Bilayer tablet is suitable for sequential release of two drugs in combination, separate two incompatible substances and also for sustained release tablet in which one layer is immediate release as initial dose and second layer is maintenance dose. The preparation of tablets in the form of multi layers is used to provide systems for the administration of drugs, which are incompatible and to provide controlled release tablet preparations by providing surrounding or multiple swelling layers. Bilayer tablet quality and GMP-requirements can vary widely. Bilayer tablets offer an excellent opportunity for manufacturers to separate themselves from their competitors, improve their products' efficacy, and protect against impersonator products.